SV119 

SV119 is a selective sigma-2 (σ₂) receptor ligand (K_i ≈ 5-10 nM). SV119 induces apoptosis in various human cancer cell lines by activating caspase-3 and promoting mitochondrial depolarization. SV119 can enhance the effects of chemotherapeutic agents such as Paclitaxel (HY-B0015), increasing their cytotoxicity against tumor cells. SV119 significantly inhibits tumor growth in mouse xenograft models, both alone and in combination. SV119 is useful in the research of cancers such as breast, prostate, and pancreatic cancer^{[1][2][3][4][5]}.

SV119 (0-10 µM) induces caspase-3/7 dependent apoptosis against Panc1, CFPAC, ASPC, PancO2 cells^[1].
SV119 has an EC₅₀ of 23.3 μM in MDA-MB-231 cells (100% maximal cytotoxicity) and 17.6 μM in MCF-7 cells (100 % maximal cytotoxicity) for sigma-2 receptor^[2].
SV119 (30 µM, 24-48 h) decreases protein levels of full-length Bid^[2].
SV119 (0-10 µM, 24 h) increases apoptosis in ASPC-1, CFPAC, Panc1, PancO2 cells in combination with Gemcitabine (HY-17026) and Paclitaxel (HY-B0015)^[4].
SV119 (10 mM, 1.5 h) reduces the fluorescence of cancer stem cell (CSC) in MDA-MB-435 cells^[5].
SV119 (SV119-PEG-AuNC/DOX, cover density (50%)) significantly reduces the formation and number of mammary cells and decreases the stemness of breast CSCs in combination with photothermal and chemotherapy in MDA-MB-435 cells^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SV119 (1 mg/mouse, i.p., once; every other day/daily, for 7 days) increases apoptosis and slows tumor growth in combination with Gemcitabine or Paclitaxel in pancreatic tumors C57BL/6 mice model^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

403.56

C₂₃H₃₇N₃O₃

913815-82-4

NCCCCCCN([C@@]1([H])C2)[C@](CCC1)([H])C[C@H]2OC(NC(C=C3C)=C(C=C3)OC)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kashiwagi H, et al. Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Mol Cancer. 2007 Jul 15;6:48.

  [2]. Zongyi Liu, et al. Sigma-2 receptor-induced cell death: a novel approach to triple-negative breast cancer treatment. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5428.

  [3]. Hiroyuki Kashiwagi, et al. Targeted delivery of proapoptotic therapeutics in pancreas cancer. Cancer Res 1 May 2008; 68 (9_Supplement): 4084.

  [4]. Kashiwagi H, et al. Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma. J Transl Med. 2009 Mar 26;7:24.

  [5]. Sun T, et al. Using SV119-gold nanocage conjugates to eradicate cancer stem cells through a combination of photothermal and chemo therapies. Adv Healthc Mater. 2014 Aug;3(8):1283-91.